Rituximab in a childhood-onset idiopathic refractory chronic inflammatory demyelinating polyneuropathy
- PMID: 21903431
- DOI: 10.1016/j.ejpn.2011.08.002
Rituximab in a childhood-onset idiopathic refractory chronic inflammatory demyelinating polyneuropathy
Abstract
Childhood-onset chronic inflammatory demyelinating polyneuropathy (CIDP) are generally responsive to conventional immunosuppressant treatments. However about 20% of patients may be refractory to several treatments and the disease has poor outcome. Rituximab is becoming a promising treatment in selected adult cases of severe CIDPs. We report the effectiveness of Rituximab in a refractory childhood-onset CIDP and we suggest this treatment as an effective choice in unresponsive childhood CIDP.
Copyright © 2011 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources